These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18254036)

  • 21. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
    Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
    JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience.
    Dowling AJ; Prince HM; Wirth A; Wolf M; Januszewicz EH; Juneja S; Seymour JF; Gates P; Smith JG
    Intern Med J; 2001 Jul; 31(5):279-89. PubMed ID: 11512599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis.
    Yin J; Wei J; Xu JH; Xiao Y; Zhang YC
    Acta Haematol; 2014; 131(2):114-25. PubMed ID: 24158006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
    Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
    Koreth J; Cutler CS; Djulbegovic B; Behl R; Schlossman RL; Munshi NC; Richardson PG; Anderson KC; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):183-96. PubMed ID: 17241924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.
    Mileshkin LR; Seymour JF; Wolf MM; Gates P; Januszewicz EH; Joyce P; Prince HM
    Leuk Lymphoma; 2005 Nov; 46(11):1575-9. PubMed ID: 16236612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
    Farquhar C; Basser R; Hetrick S; Lethaby A; Marjoribanks J
    Cochrane Database Syst Rev; 2003; (1):CD003142. PubMed ID: 12535458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
    Mounier N; Haioun C; Cole BF; Gisselbrecht C; Sebban C; Morel P; Marit G; Bouabdallah R; Ravoet C; Salles G; Reyes F; Lepage E
    Blood; 2000 Jun; 95(12):3687-92. PubMed ID: 10845898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
    Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
    Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.
    Chakraborty R; Siddiqi R; Willson G; Gupta S; Asghar N; Husnain M; Aljama MA; Behera TR; Anwer F; Perrot A; Riaz IB
    Cancer; 2022 Jun; 128(12):2288-2297. PubMed ID: 35377484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
    Kewalramani T; Zelenetz AD; Hedrick EE; Donnelly GB; Hunte S; Priovolos AC; Qin J; Lyons NC; Yahalom J; Nimer SD; Moskowitz CH
    Blood; 2000 Oct; 96(7):2399-404. PubMed ID: 11001890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
    Bohlius J; Reiser M; Schwarzer G; Engert A
    Cochrane Database Syst Rev; 2004; (1):CD003189. PubMed ID: 14974009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma.
    Bohlius J; Reiser M; Schwarzer G; Engert A
    Cochrane Database Syst Rev; 2002; (4):CD003189. PubMed ID: 12519588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis.
    Faussner F; Dempke WC
    Anticancer Res; 2012 May; 32(5):2103-9. PubMed ID: 22593496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
    Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
    Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.